2-[(2-oxo-4-phenyl-2h-chromene-7-yl) oxy] propanamide derivatives

By targeting mitochondrial RNA polymerase inhibitors, the problem that the prior art is difficult to effectively target CSCs and senescent cells is solved, efficient inhibition of a variety of cancer cells and tumor recurrence prevention is achieved, and the effectiveness of anti-cancer treatment is significantly improved.

CN119072469APending Publication Date: 2024-12-03LUNELLA BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032595.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-30
Filing Date
2023-03-23
Publication Date
2024-12-03

Smart Images

  • Figure CN119072469A_ABST
    Figure CN119072469A_ABST
Patent Text Reader

Abstract

Disclosed are 2-[(2-oxo-4-phenyl-2H-chromene-7-yl) oxy] propanamide derivatives, in which at least one of R1 to R4 contains an amino group, and methods for preparing the same. These derivatives can be used to target and eliminate cancer stem cells, and can be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of tumor recurrence and metastasis and / or preventing tumor recurrence and metastasis. The compounds disclosed herein have demonstrated to inhibit tumor cell spherogenic ability, migration, and stemness-related signaling in cancer stem cells. These properties result from selective inhibition of mitochondrial transcription against mitochondrial RNA polymerase (POLRMT) in cancer cells. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to 2-[(2-oxo-4-phenyl-2H-chromen-7-yl)oxy]propanamido derivatives that inhibit the proliferation of cancer stem cells (CSCs) and senescent cells. Background Art

[0002] The biological process of aging continues to receive great attention from the scientific and medical research community. Physiological aging is at least partially related to increased rates of oxidative damage to cellular components (including DNA, lipids, proteins, etc.). The increase in oxidative damage creates an imbalance that disrupts the self-regulatory process at the cellular level. Further, aging is associated with the accumulation of lipofuscin in the cytoplasm of neurons. Modern research also shows that aging is the result of naturally occurring DNA damage, which leads to abnormal DNA changes and accumulates over time. Damage to both mitochondrial and nuclear DNA can indirectly lead to aging by increasing apoptosis and cellular senescence, as well as directly by increasing cell dysfunction. Accumulated DNA damage can lead to cell loss, and in surviving cells, loss of gene expression and mutations can have an impact in cells that do not divide frequently, thereby producing signs of aging. When aging cells stop cell division, the results of cellular aging are believed to occur after various environmental damage events, abnormal cell growth, autophagy, and oxidative stress. The Senescence Associated Secretory Phenotype (SASP) is a characteristic of senescent cells and results in proteotoxic impairment of healthy cell functions, including inflammatory or anti-inflammatory and tumor or anti-tumor effects, depending on many factors. The effects of chronic inflammation associated with the SASP affect the normal ability of the immune system to remove senescent cells, and cells that provide immune function can be recruited into senescent cells by the SASP. Biomarkers of cellular senescence have been found to accumulate as mammals age and contribute to a range of age-related diseases, including Alzheimer's disease, lateral sclerosis, and type 2 diabetes. And for cells that divide frequently, accumulated DNA damage can be an important cause of cancer.

[0003] Therefore, aging increases the possibility of developing cancer, and researchers have worked hard to develop new anti-cancer and anti-aging or senescent cell lysis methods (senolytic) treatments. Traditional cancer therapies (e.g., radiation, alkylating agents such as cyclophosphamide, and antimetabolites such as 5-fluorouracil) have attempted to selectively detect and eradicate rapidly growing cancer cells by interfering with the cellular mechanisms involved in cell growth and DNA replication. Other cancer therapies have used immunotherapies that selectively bind mutated tumor antigens to rapidly growing cancer cells (e.g., monoclonal antibodies). Unfortunately, tumors often recur after these treatments, at the same or different one or more sites, indicating that not all cancer cells are eradicated. Especially cancer stem cells, which survive and cause treatment failure for various reasons. Recurrence can be due to insufficient chemotherapy doses and / or the emergence of cancer clones that are resistant to treatment. Therefore, new cancer treatment strategies are needed to overcome the shortcomings of traditional therapies.

[0004] Advances in mutation analysis have allowed for in-depth studies of genetic mutations that occur during cancer progression. Despite an understanding of the genomic landscape, modern oncology has difficulty identifying major driver mutations between cancer subtypes. The harsh reality seems to be that each patient's tumor is unique and that a single tumor can contain multiple different clonal cells. Therefore, new approaches that emphasize the commonalities between different cancer types are needed. Targeting metabolic differences between tumors and normal cells holds promise as a new cancer treatment strategy. Analysis of transcriptional profiling data from human breast cancer samples showed elevated transcription of more than 95 mRNAs associated with mitochondrial biogenesis and / or mitochondrial translation. Sotgia et al. Cell Cycle, 11(23):4390-4401(2012). In addition, of the 95 upregulated mRNAs, more than 35 upregulated mRNAs encode mitochondrial ribosomal proteins (MRPs). Proteomic analysis of human breast cancer stem cells also showed significant overexpression of several mitotic ribosomal proteins and other proteins associated with mitochondrial biogenesis. Lamb et al. Oncotarget, 5(22): 11029-11037 (2014).

[0005] With respect to the search for therapeutic targets for anticancer therapy and senescent cell lysis, cancer cell mitochondrial metabolism is the target of recent exploratory studies. Mitochondria are extremely dynamic organelles that constantly divide, elongate and connect to each other to form tubular networks or fragmented particles in order to meet the needs of the cell and adapt to the cellular microenvironment. The balance of mitochondrial fusion and fission dictates the morphology, abundance, function and spatial distribution of mitochondria, thus affecting a large number of important mitochondria-dependent biological processes, such as adenosine triphosphate (ATP) production, mitosis, apoptosis and calcium homeostasis. In turn, the dynamics of mitochondria can be regulated by mitochondrial metabolism, respiration and oxidative stress.

[0006] ATP is the universal bioenergetic "currency" of all living cells and tissues, including microorganisms such as prokaryotic bacteria and eukaryotic yeast. In eukaryotes, mitochondrial organelles serve as the "powerhouse" of the cell. Mitochondria produce large amounts of ATP via the TCA cycle and oxidative phosphorylation (OXPHOS), while glycolysis contributes a small amount of ATP. Conversely, mitochondrial dysfunction induces ATP depletion, which leads to mitochondrial-driven apoptosis (programmed cell death) and / or necrosis. Therefore, we propose that ATP depletion therapy may be a viable strategy for targeting and eradicating cancer cells, even the "fittest" ones.

[0007] In MCF7 breast cancer cells, mitochondria-driven OXPHOS contributes 80%-90% of ATP production under normoxic conditions, while glycolysis contributes only the remaining 10%-20%. Thus, like normal cells, cancer cells are highly dependent on mitochondrial ATP production. However, whether ATP levels in cancer cells contribute to 3D anchorage-independent growth and cell migration, two hallmarks of metastatic spread, remains largely unknown.

[0008] Therefore, there is a need for new anti-aging compositions and methods that treat aging at the cellular level, overcoming accumulated oxidative and DNA damage and the many adverse effects of aging.

[0009] Further, there is a need for therapeutic agents that target unhealthy senescent cells and the SASP, reduce the accumulation of cellular senescence, and counteract chronic senescence.

[0010] Further, there is a need for therapeutic agents that target a wide range of CSCs through their common features regardless of cancer type.

[0011] Further, there is a need for therapeutic agents that inhibit the proliferation of CSCs, including circulating tumor cells and tumor-initiating cells that have the potential to lead to tumor recurrence and / or metastasis. Summary of the invention

[0012] In view of the foregoing background, the purpose of the present disclosure is to describe therapeutic agents or compounds that can be used to reduce the accumulation of cellular senescence and inhibit CSC proliferation. The purpose of the present disclosure is to describe therapeutic agents for eradicating CSC and senescent cells. The purpose of the present disclosure is to describe therapeutic agents for preventing tumor recurrence and metastasis and reducing the possibility of tumor recurrence and metastasis. Another purpose of the present disclosure is to describe compositions (such as pharmaceutical compositions) and methods for treating and preventing cancers including tumor recurrence and / or metastasis. Another purpose of the present disclosure is to describe compositions (such as pharmaceutical compositions) and methods for therapeutic agents for senescent cell lysis methods.

[0013] Compounds that can be used as therapeutic agents with anticancer activity, pharmaceutical compositions containing such therapeutic agents, methods for synthesizing such compounds, and methods for treating cancer are described herein. The embodiments of the therapeutic agents described herein can be compared with the formula shown below to demonstrate the unexpected beneficial advantages of the present method:

[0014]

[0015] A known orally active mitochondrial RNA polymerase (POLRMT) inhibitor. The compound was first described in Bonekamp, ​​NA, Peter, B., Hillen, HS et al., Small-molecule inhibitors of human mitochondrial DNA transcription. Nature 588, 712–716 (2020), which is incorporated herein by reference in its entirety. As a POLRMT inhibitor, the compound inhibits mitochondrial DNA expression. The IUPAC name for this embodiment is 3-piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)-, and has been assigned CAS Registry Number 2304621-06-3.

[0016] Under the present method, some embodiments of the compound or a pharmaceutically acceptable salt thereof may have a generic chemical structure of Formula 1, as shown below:

[0017] in:

[0018] R1 and R2 may be the same or different and are selected from halogen, CF2H, -CF3, -OCF2H, -OCF3, substituted or unsubstituted C5-C18 carboxyl, substituted or unsubstituted C5-C18 alkane, substituted or unsubstituted C5-C18 olefin, substituted or unsubstituted C5-C18 cycloolefin, substituted or unsubstituted C5-C18 alkyne, substituted or unsubstituted C5-C18 ketone, substituted or unsubstituted C5-C18 aldehyde, substituted or unsubstituted C5-C18 ether, substituted or unsubstituted C5-C18 ester, substituted or unsubstituted C5-C18 amine, substituted or unsubstituted C5-C18 amide, substituted or unsubstituted C5-C18 alkylamide, monocyclic or polycyclic aromatic hydrocarbon, heteroaromatic hydrocarbon, phenol or benzoic acid; and

[0019] R3 and R4 may be identical or different and are selected from hydrogen, substituted or unsubstituted C2-C18-alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C18 carboxyl, substituted or unsubstituted C2-C18 alkene, substituted or unsubstituted C2-C18 alkyne, substituted or unsubstituted C2-C18 ketone, substituted or unsubstituted C2-C18 aldehyde, substituted or unsubstituted C2-C18 ether, substituted or unsubstituted C2-C18 ester, substituted or unsubstituted C2-C18 amine, substituted or unsubstituted C2-C18 amide, substituted or unsubstituted C2-C18 alkylamide, substituted or unsubstituted phenol or benzoic acid, or one of R3 and R4 is a radical and the other of R3 and R4 is H or C2-C5 alkyl; or R3 and R4 form a substituted or unsubstituted C5 or C6 heterocycle; or R3 and R4 form a group or NR3R4 is replaced by OH;

[0020] Provided that at least one of R1 and R2 is a substituted or unsubstituted C5-C18 amide, or at least one of R3 and R4 is a group And the other of R3 and R4 is hydrogen or C2-C5 alkyl.

[0021] It should be understood that in some embodiments, the lactic acid portion of the propionamide base of Formula 1 can be modified with certain side chains - or the methyl group can be replaced with hydrogen. For example, some embodiments of the compounds or pharmaceutically acceptable salts thereof according to the present method have a family chemical structure of Formula 2, as shown below:

[0022] wherein R1, R2, R3 and R4 are as described above for Formula 1, and R5 and R6 may be the same or different and are selected from hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C10 carboxyl, substituted or unsubstituted C2-C10 alkene, substituted or unsubstituted C2-C10 alkyne, substituted or unsubstituted C2-C10 ketone, substituted or unsubstituted C2-C10 aldehyde, substituted or unsubstituted C2-C10 ether, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C2-C10 amine, substituted or unsubstituted C2-C10 amide, substituted or unsubstituted C2-C10 alkylamide, substituted or unsubstituted phenol, or benzoic acid.

[0023] The following paragraphs illustrate various examples of the present method. It should be understood that the amide chain length can vary from C5 to C18. In some embodiments, for example, the therapeutic agent has the following formula:

[0024]

[0025] As another example, in some embodiments, the therapeutic agent has the formula:

[0026]

[0027] As another example, some embodiments of the therapeutic agent have the formula:

[0028]

[0029] As another example, some embodiments of the therapeutic agent have the formula:

[0030]

[0031] In further examples, in some embodiments, the therapeutic agent has the formula:

[0032]

[0033] As another example, some embodiments of the therapeutic agent have the formula:

[0034] As described above, it should be understood that some embodiments of the therapeutic agent may have C5-C18 amides. In laboratory testing, amides shorter than C5 and longer than C18 have limited therapeutic activity. In preferred embodiments, C10-C16 amides, and particularly C12-C15 amides, show significantly improved therapeutic activity relative to the baseline compound determined in paragraph

[0014] above.

[0035] In some embodiments, one of R3 and R4 is a group and the other is H or C2-C5 alkyl. For example, in the following exemplary structure, R1 is Cl, R2 is isobutyl carbamate, and R3 is R4 is C2.

[0036]

[0037] In the above examples, R2 can be varied as described above. For example, in another exemplary structure, R2 can be tert-butyl carbamate.

[0038] The method can also be used to treat and / or prevent tumor recurrence and / or metastasis. Anticancer treatments often fail due to tumor recurrence or metastasis, especially after surgery. It is understood that CSC mitochondrial activity is at least partly responsible for the failure of treatment. Embodiments of the method can be used in situations where conventional cancer treatments have failed, and / or in combination with or before anticancer treatments to prevent treatment failure due to tumor recurrence and / or metastasis or to reduce the likelihood of treatment failure due to tumor recurrence and / or metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figures 1A-1C Shown are the results of mammosphere formation, SRB assay on MCF-7 cells, and SRB assay on BJ1-hTERT cells for embodiments of compound [I].

[0040] Figure 2A-2C Shown are the results of mammary cell sphere formation, SRB assay on MCF-7 cells, and SRB assay on BJ1-hTERT cells for embodiments of compound [II].

[0041] Figures 3A-3C Shown are the results of mammary cell sphere formation, SRB assay on MCF-7 cells, and SRB assay on BJ1-hTERT cells for embodiments of compound [III].

[0042] Figure 4A and Figure 4BShown are the results of breast cell sphere formation and SRB assay on MCF-7 cells (2D) for an embodiment of compound [IV].

[0043] Figures 5A-5C Shown are the results of mammary cell sphere formation, SRB assay on MCF-7 cells, and SRB assay on BJ1-hTERT cells for embodiments of compound [V].

[0044] Fig. 6A and Figure 6B Shown are the results of mammary cell sphere formation and SRB assay on MCF-7 cells for embodiments of compound [VI].

[0045] Fig. 7A and Figure 7B Shown are the results of mammary cell sphere formation and SRB assay on MCF-7 cells for embodiments of compound [VII].

[0046] Figure 8 Quantitative assessment of tumor growth using the CAM assay for different concentrations of embodiments of the present methods is shown.

[0047] Fig. 9 Quantitative assessment of metastatic invasiveness using the CAM assay is shown for different concentrations of embodiments of the present methods.

[0048] Fig.10 Toxicity assessment using the CAM assay is shown for different concentrations of embodiments of the present methods.

[0049] Fig.11A -D shows the results of mitochondrial respiration, basal respiration, maximal respiration and ATP production for metabolic flux analysis of adherent MCF7 cells treated with compounds according to the present method.

[0050] Fig. 12A -D shows the results of glycolytic functional analysis for treatment with compounds according to the present method. DETAILED DESCRIPTION

[0051] The following description fully describes the embodiments of the method in detail to achieve the practice of the method. Although the method is described with reference to these specific embodiments, it should be understood that the method can be implemented in different forms, and this specification should not be interpreted as limiting any of the appended claims of the specific embodiments set forth herein. On the contrary, these embodiments are provided so that the disclosure will be comprehensive and complete, and will fully convey the scope of the method to those skilled in the art.

[0052] This specification uses various terms that should be understood by those of ordinary skill in the art. For the avoidance of doubt, the following clarification is made.

[0053] The term "cancer" refers to a physiological condition in mammals that is typically characterized by uncontrolled cell growth. This definition includes both benign and malignant tumors. Examples of cancer include cancer types, lymphomas, blastomas (including medulloblastoma and retinoblastoma), sarcomas (including liposarcoma and synovial sarcoma), neuroendocrine tumors (carcinoid, gastrin-producing including but not limited to tumors and islet cell carcinomas), sarcomas, schwannomas (including acoustic neuromas), medullary carcinomas, adenocarcinomas, melanomas, and leukemias or lymphocytic tumors. Specific examples of cancer include bladder cancer, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung cancer including squamous cell lung cancer, peritoneal cancer, hepatocellular carcinoma, gastric cancer including gastrointestinal cancer or gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer (including metastatic breast cancer), colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, renal cancer (kidney cancer) or renal cancer (kidney cancer), prostate cancer, genital cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, testicular cancer, esophageal cancer, bile duct tumors, as well as head and neck cancer and multiple myeloma.

[0054] As used herein, the term "tumor" refers to the growth and proliferation of neoplastic cells, whether malignant or benign, including precancerous and cancerous cells and tissues.

[0055] The term "metastasis" refers to the spread of cancer from the primary site to other parts of the body. Cancer cells can escape from the primary tumor, penetrate lymphatic and blood vessels, circulate through the blood, and grow or "metastasize" in distant lesions of normal tissues in other parts of the body. Metastasis can be local or distant. Metastasis is a continuous process that requires tumor cells to escape from the primary tumor, travel through the blood, and stop at a distant site. At this new site, the cells can establish a blood supply and grow to form a life-threatening mass. Both stimulatory and inhibitory molecular pathways within the tumor cells control this behavior, and the interaction between the tumor cells and the host cells at the distant site is also important.

[0056] The terms "treat", "treated", "treating" and "treatment" include the reduction or alleviation of at least one symptom associated with or caused by the condition, disorder or disease being treated, particularly cancer. In certain embodiments, treatment includes the elimination and / or alleviation of at least one symptom associated with or caused by the cancer being treated by the compounds of the present invention. In some embodiments, treatment includes causing the death of a class of cells, such as senescent cells, SASP cells or CSCs that may be involved in the metastasis or recurrence of a particular cancer in a host, and can be achieved by preventing further proliferation of senescent cells and / or cancer cells, and / or inhibiting CSC function by, for example, depriving such cells of mechanisms for energy production. For example, treatment can be the reduction of one or more symptoms of a cancer, or the complete eradication of a cancer. As another example, the present method can be used to inhibit mitochondrial metabolism in cancer, eradicate (e.g., kill at a rate greater than the proliferation rate) CSCs in cancer, eradicate TICs in cancer, eradicate circulating tumor cells in cancer, inhibit proliferation of cancer, target and inhibit CSCs, target and inhibit TICs, target and inhibit circulating tumor cells, prevent metastasis or reduce the likelihood of metastasis, prevent recurrence, sensitize cancer to chemotherapy, sensitize cancer to radiotherapy, sensitize cancer to phototherapy. As another example, the treatment can reduce the accumulation of senescent cells, and / or reduce the rate at which senescent cells accumulate.

[0057] In the context of tumor recurrence and / or metastasis, the terms "prevention" and "reducing the likelihood" refer to reducing the presence of CSCs, TICs, and circulating tumor cells that may be involved in recurrence or metastasis in a subject to a level that is less likely to recur and / or metastasize from the primary site relative to a control group (i.e., no treatment to prevent tumor recurrence and / or metastasis, or to reduce the likelihood of tumor recurrence and / or metastasis). In practice, the treatments described herein to prevent tumor recurrence and / or metastasis, and / or reduce the likelihood of tumor recurrence and / or metastasis target and inhibit or eradicate CSCs, TICs, and inhibit circulating tumor cells.

[0058] The terms "cancer stem cells" and "CSC" refer to a subpopulation of cancer cells within a tumor that have the ability to self-renew, differentiate, and become tumorigenic when transplanted into an animal host. CSCs have increased mitochondrial mass, enhanced mitochondrial biogenesis, and increased activity of mitochondrial protein translation compared to "bulky" cancer cells. As used herein, "circulating tumor cells" are cancer cells that shed from a primary tumor into the vasculature or lymphatics and are carried throughout the body in the blood circulation. The CellSearch Circulating Tumor Cell Test can be used to detect circulating tumor cells.

[0059] As used herein, the phrase "pharmaceutically effective amount" means the amount required to administer to a host or a cell, tissue or organ of a host to obtain a therapeutic result (such as, regulating, adjusting or inhibiting protein kinase activity, for example, protein kinase activity inhibition, or treatment of cancer). A physician or veterinarian with ordinary skills in the art can easily determine and prescribe the effective amount of the pharmaceutical composition required for a given subject using methods known and available in the art. For example, a physician or veterinarian can start the dose of the compound of the present invention used in the pharmaceutical composition at a level lower than the level required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. After studying this disclosure, the determination of the effective dose of the drug is considered to be within the authority of a person with ordinary skills in the art.

[0060] As used herein, the phrase "therapeutic agent" refers to an embodiment of the compound described herein, which may include a pharmaceutically acceptable salt or an isotopic analog thereof. It should be understood that, as known to the general level of the art, the therapeutic agent may be administered to the subject by any appropriate method. It should also be understood that the amount of the therapeutic agent and its administration time may depend on the individual subject being treated (e.g., age and weight, and other factors), the mode of administration, the pharmacokinetic properties of the specific therapeutic agent, and the judgment of the doctor who prescribes the prescription. Therefore, due to the variability between subjects, any dosage described herein is intended to be used as an initial guide, and the doctor can titrate the dosage of the therapeutic agent to achieve the treatment that the doctor considers suitable for the subject. When considering the degree of treatment required, the doctor can balance various factors (such as, the age and weight of the subject, the presence of pre-existing diseases and other diseases). Pharmaceutical preparations can be prepared for any desired route of administration, including but not limited to, oral, intravenous or aerosol administration, as discussed in more detail below.

[0061] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil , olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other nontoxic compatible substances used in pharmaceutical preparations.

[0062] The phrase "pharmaceutically acceptable salts" are relatively nontoxic inorganic and organic base addition salts of the compounds of the present method. Pharmaceutically acceptable salts can be formed by, for example, reacting the compound in the form of a free acid with a base (such as, a pharmaceutically acceptable metal cation hydroxide or carbonate), ammonia or a pharmaceutically acceptable amine. For example, representative alkali salts or alkaline earth salts include sodium salts, potassium salts, calcium salts, magnesium salts and aluminum salts. Examples of amines that can be used as base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine. Of course, it should be understood that other salts may also be used, and those of ordinary skill in the art can use methods known in the art to identify suitable salt forms without departing from the present method.

[0063] As used herein, a "fatty acid" moiety is a carboxylic acid having a saturated or unsaturated fatty chain. Examples of fatty acids include short-chain fatty acids (i.e., having 5 or fewer carbon atoms in the chemical structure), medium-chain fatty acids (i.e., having 6-12 carbon atoms in the chemical structure), and other long-chain fatty acids (i.e., having 13-21 carbon atoms in the chemical structure). Examples of saturated fatty acids include lauric acid (CH3(CH2) 10 COOH), palmitic acid (CH3(CH2) 14 COOH), stearic acid (CH3(CH2)16 COOH) and myristic acid (CH3(CH2) 12 COOH). Oleic acid (CH3(CH2)7CH=CH(CH2)7COOH) is a naturally occurring unsaturated fatty acid. It should be understood that in some embodiments, the compounds of the present method include linear, saturated fatty acids or amide groups, and preferably linear saturated fatty acids or amide groups having 5 to 18 carbon atoms, more preferably 10 to 16 carbon atoms, and even more preferably 12 to 15 carbon atoms. In some preferred embodiments, the linear, saturated fatty acid is myristic acid, or the amide is myristic acid having 14 carbon atoms.

[0064] Recent developments have identified a new drug (first-in-class) inhibitor of mitochondrial transcription that targets mitochondrial RNA polymerase (POLRMT), which is the gene product in the OXPHOS system responsible for mitochondrial gene expression and mitochondrial biogenesis. The inhibitor has been used in four-week tests in mice. Oral treatment with the compound did not show evidence of dysfunction or toxicity of OXPHOS in mice, but showed a powerful anti-tumor effect in human cancer cell xenografts.

[0065] Embodiments of compounds disclosed herein can be used as therapeutic agents to selectively eradicate CSCs for treating and / or preventing tumor recurrence and / or metastasis. Data have proven that compounds disclosed herein have anticancer activity and are suitable for use as therapeutic agents for anticancer treatments including treating and / or preventing tumor recurrence and metastasis. Data described herein demonstrate anticancer activity by determining the inhibition of MCF7 cells via mammary cell sphere formation, and demonstrate cell viability using mercapto-rhodamine B assay (also known in the art, and referred to herein as SRB test). This assay measures the amount of residual protein attached to a tissue culture dish and is a surrogate marker for cell viability.

[0066] In the context of the present methods, embodiments of the therapeutic compound or a pharmaceutically acceptable salt thereof may have a generic chemical structure of Formula 1, as shown below:

[0067] in:

[0068] R1 and R2 may be the same or different and may be halogen, CF2H, -CF3, -OCF2H, -OCF3, substituted or unsubstituted C5-C18 carboxyl, substituted or unsubstituted C5-C18 alkane, substituted or unsubstituted C5-C18 olefin, substituted or unsubstituted

[0069] C5-C18 cycloolefins, substituted or unsubstituted C5-C18 alkynes, substituted or unsubstituted C5-C18 ketones, substituted or unsubstituted

[0070] C5-C18 aldehyde, substituted or unsubstituted C5-C18 ether, substituted or unsubstituted C5-C18 ester, substituted or unsubstituted C5-C18 amine, substituted or unsubstituted C5-C18 amide, substituted or unsubstituted C5-C18 alkylamide, monocyclic or polycyclic aromatic hydrocarbon, heteroaromatic hydrocarbon, phenol or benzoic acid; and

[0071] R3 and R4 may be identical or different and may be hydrogen, substituted or unsubstituted C2-C18-alkyl, substituted or unsubstituted

[0072] C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C18 carboxyl, substituted or unsubstituted C2-C18 alkene, substituted or unsubstituted C2-C18 alkyne, substituted or unsubstituted C2-C18 ketone, substituted or unsubstituted C2-C18 aldehyde, substituted or unsubstituted C2-C18 ether, substituted or unsubstituted C2-C18 ester, substituted or unsubstituted C2-C18 amine, substituted or unsubstituted C2-C18 amide, substituted or unsubstituted C2-C18 alkylamide, substituted or unsubstituted phenol or benzoic acid, or

[0073] One of R3 and R4 is a group

[0074] and the other of R3 and R4 is H or C2-C5 alkyl; or R3 and R4 form a substituted or unsubstituted

[0075] Substituted C5 or C6 heterocycle; or R3 and R4 form a group or NR3R4 is OH;

[0076] Provided that at least one of R1 and R2 is a substituted or unsubstituted C5-C18 amide, or at least one of R3 and R4 is

[0077] One is selected from the group consisting of and the other is H or C2-C5 alkyl:

[0078]

[0079] In some preferred embodiments, at least one of R1 and R2 is a substituted or unsubstituted C5-C18 amide, or at least one of R3 and R4 is a group and the other is H or C2-C5 alkyl.

[0080] Compounds having the generic structure of Formula 1 can be prepared according to the following general reaction scheme, wherein substituted benzoic acids can be used as starting compounds. Functional groups R1, R2, R3 and R4 can be as described above.

[0081]

[0082] It will be appreciated that other synthetic methods may be used to obtain the compounds of the present methods.

[0083] The following compounds are exemplary of therapeutic agents according to the present method, wherein R1 is a halogen and R2 is an alkylamide group. It should be understood that R1 and R2 may occupy other positions on the phenyl group without departing from the present method.

[0084]

[0085] The following compounds are illustrative of therapeutic agents according to the present method, which demonstrate variations in R3 and R4 and various enantiomers. As will be appreciated by those of ordinary skill in the art, for certain embodiments, R1 and R2 refer to functional groups, and the 'R' and 'S' designations represent the enantiomers of a stereocenter.

[0086]

[0087]

[0088]

[0089] Compounds having a family structure of Formula 1, wherein R1 is a halogen (e.g., chlorine or fluorine) and R2 is an alkylamide, can be prepared according to the following general reaction scheme, wherein a substituted benzoic acid can be used as a starting compound. Functional groups R1, R2, R3 and R4 can be as described above, and specific examples are described below.

[0090]

[0091] It will be appreciated that the halogen and alkylamide may occupy various positions on the phenyl group in addition to those exemplified above.

[0092] As another example, some embodiments of the therapeutic agents described herein can be prepared according to the following reaction schemes.

[0093]

[0094] In the illustrated embodiment, R1 is fluorine, R2 is alkylamide, R3 is ethyl, and R4 is (dimethylamino)propylamide. As with other exemplary embodiments described herein, it will be appreciated that halogens and alkylamides may occupy different positions on the phenyl group in addition to those shown in the above examples.

[0095] The compounds of the present invention show significantly improved therapeutic activity relative to compound [I], the chemical structure of which is as follows:

[0096]

[0097] Compound [I], 3-piperidinic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)-(CAS No.: 2304621-06-3) has an IC of about 50 μM against MCF-7 cells 50 . Figures 1A-1C The results of mammary cell sphere formation, SRB assay on MCF-7 cells and SRB assay on BJ1-hTERT cells for compound [I] are shown. Figure 1A It can be concluded that compound [I] showed an inhibitory effect on MCF-7 cells at a concentration of 5 μM, and achieved more than 50% inhibition at a concentration of 100 μM. Figure 1B and Figure 1C It was shown that compound [I] exhibited no cytotoxicity towards MCF-7 and BJ1-hTERT cells at all tested concentrations between 1 μM and 100 μM.

[0098] In some embodiments, the therapeutic agent may take the form of the following compound [II], (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]piperidine-3-carboxylic acid, which has the following chemical structure:

[0099]

[0100] Compound II, (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionyl]piperidine-3-carboxylic acid, can be synthesized according to the following process. In step 1, ethyl (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionyl]piperidine-3-carboxylate is prepared as an intermediate. NMM (35.5 μl, 0.32 mmol) and EDC hydrochloride (62 mg, 0.32 mmol) were added to a stirred solution of (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (147 mg, 0.25 mmol) and (S)-ethylpiperidine-3-carboxylate (1 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 16 hours, diluted with EtOAc (40 ml), washed with 2M HCl (15 ml), water (15 ml), saturated NaHCO3 (15 ml), brine (15 ml), dried over MgSO4, filtered and the filtrate evaporated under reduced pressure to give a crude product. Purification on silica gel (30% EtOAc in isohexane) gave ethyl (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]piperidine-3-carboxylate (19.6 mg). LC-MS 709.4 [M+1]+, RT 6.86 min.

[0101] In step 2, (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]piperidine-3-carboxylic acid is prepared from the intermediate. 1 M NaOH (75 μl, 0.075 mmol) is added to a stirred solution of ethyl (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]piperidine-3-carboxylate (19 mg, 0.027 mmol) in THF (1.5 ml) and MeOH (0.5 ml) at room temperature, and the mixture is stirred for 16 hours. The solvent was evaporated under reduced pressure, the residue was suspended in EtOAc (30 ml), acidified with 2M HCl (10 ml), the extract was washed with brine (10 ml), dried over MgSO4, the solid residue was removed by filtration and the solvent was evaporated under reduced pressure to give (3S)-1-[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]piperidine-3-carboxylic acid (17.3 mg) as a solid. LC-MS 681.4 [M+1]+, RT 6.39 min.

[0102] Figure 2A-2C The results of mammary cell sphere formation, SRB assay on MCF-7 cells and SRB assay on BJ1-hTERT cells for compound [II] are shown. Figure 2A As can be seen from the results, compound [II] showed a dose-dependent inhibitory effect on MCF-7 cells at all tested concentrations, ranging from 0.1 μM to 100 μM. Compound [II] achieved greater than 50% inhibition at a concentration of 10 μM and 100% inhibition at 100 μM. 50 Compound [II] was 10 times more potent than compound [I] in inhibiting MCF-7 breast cell sphere formation. Figure 2B and Figure 2C It was shown that compound [II] exhibited cytotoxicity to MCF-7 and BJ1-hTERT cells starting from 50 μM.

[0103] In some embodiments, the therapeutic agent can take the form of the following compound [III], tert-butyl-N-[3-chloro-4-[7-[(1R)-2-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]carbamate, which has the following chemical structure:

[0104]

[0105] Compound [III] was prepared from 2-chloro-4-nitrobenzoic acid according to the method in Advance Synthesis and Catalysis, 2014, Vol. 356, No. 11-12, pp. 2437-2444, and the crude product 2-chloro-4-nitro-benzoyl chloride was a light brown oil (11.78 g). According to the method in step 1 of compound [IV], ethyl 3-(2-chloro-4-nitro-phenyl)-3-oxo-propionate was prepared from the crude product 2-chloro-4-nitro-benzoyl chloride to obtain ethyl 3-(2-chloro-4-nitro-phenyl)-3-oxo-propionate (11.04 g) as a light brown solid. LC-MS 272.0 [M+1] +, RT 5.39 min.

[0106] Next, 4-(2-chloro-4-nitro-phenyl)-7-hydroxy-2-one was prepared from ethyl 3-(2-chloro-4-nitro-phenyl)-3-oxo-propionate according to the method in step 2 of compound [IV] to give 4-(2-chloro-4-nitro-phenyl)-7-hydroxy-chromen-2-one (5.85 g) as a purple solid. LC-MS 318.0 [M+1]+, RT 5.18 min.

[0107] Next, 4-(4-amino-2-chloro-phenyl)-7-hydroxy-chromen-2-one was prepared from 4-(2-chloro-4-nitro-phenyl)-7-hydroxy-chromen-2-one according to the method in step 3 of compound [IV] to give 4-(4-amino-2-chloro-phenyl)-7-hydroxy-chromen-2-one (3.02 g) as a dark reddish brown solid. LC-MS 287.8 [M+1]+, RT 4.43 min.

[0108] Ethyl (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxypropanoate was prepared according to the method in step 4 of compound [IV] using 4-(4-amino-2-chloro-phenyl)-7-hydroxy-chromen-2-one to give ethyl (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxypropanoate (1.57 g) as a light brown solid. LC-MS 388.0 [M+1]+, RT 5.27 min.

[0109] Next, ethyl (2R)-2-[4-[4-(tert-butoxycarbonylamino)-2-chloro-phenyl]-2-oxo-chromen-7-yl]oxy propionate was prepared. Boc anhydride (0.37 g, 1.70 mmol) was added to a stirred solution of ethyl (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy propionate (0.26 g, 0.70 mmol) and DMAP (0.21 g, 1.70 mmol) DCM (20 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 16 hours and the solvent was evaporated under reduced pressure to obtain a crude product. The residue was dissolved in EtOAc (40 ml), washed with 2M HCl (20 ml), saturated NaHCO3 (20 ml), brine (20 ml), dried over MgSO4, filtered and the solvent was evaporated under reduced pressure to obtain a crude product. Trituration with n-pentane gave ethyl (2R)-2-[4-[4-(tert-butoxycarbonylamino)-2-chloro-phenyl]-2-oxo-chromen-7-yl]oxypropanoate (0.54 g). LC-MS 488.0 [M+1]+, RT 6.60 min.

[0110] As the next step, (2R)-2-[4-[4-(tert-butoxycarbonylamino)-2-chloro-phenyl]-2-oxo-chromen-7-yl]oxypropionic acid was prepared from ethyl (2R)-2-[4-[4-(tert-butoxycarbonylamino)-2-chloro-phenyl]-2-oxo-chromen-7-yl]oxypropanoate according to the method in step 6 of compound [IV] to give (2R)-2-[4-[4-(tert-butoxycarbonylamino)-2-chloro-phenyl]-2-oxo-chromen-7-yl]oxypropionic acid as a light brown solid. LC-MS 460.0 [M+1]+, RT 5.98 min.

[0111] Finally, following the procedure in step 3 of Example 6, N-[3-chloro-4-[7-(1R)-2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-7-yl]oxypropanoic acid was prepared. To obtain tert-butyl N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]carbamate (structure as follows, wherein "Boc" represents tert-butyloxycarbonyl) (0.15 g) as a light brown solid. LC-MS 615.2 [M+1]+, RT 4.38 min.

[0112]

[0113] Figures 3A-3C The results of mammary cell sphere formation, SRB assay results on MCF-7 cells, and SRB assay results on BJ1-hTERT cells of compound [III] are shown. Figure 3A As can be concluded from the results, compound [III] showed a dose-dependent inhibitory effect on MCF-7 cells at all tested concentrations, ranging from 1 μM to 10 μM. The IC 50 The concentration was between 1 μM and 2.5 μM, and at a concentration of 10 μM, it was 20 times higher than that of compound [I]. Furthermore, compound [III] inhibited MCF-7 cells by 100%. Figure 2B and Figure 2C It was shown that compound [III] exhibited cytotoxicity to MCF-7 and BJ1-hTERT cells starting from 10 μM.

[0114] In some embodiments, the therapeutic agent may take the form of the following compound [IV], N-[2-[7-[(1R)-2-[3-(dimethylamino)propylcarbamoyl-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]-5-fluoro-phenyl]tetradecanoamide, which has the following chemical structure:

[0115]

[0116] Compound [IV] was prepared using compound [VII], (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid as an intermediate, and its synthesis was as follows. NMM (23 μl, 0.21 mmol) and EDC hydrochloride (27 mg, 0.14 mmol) were added to a stirred solution of (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (60 mg, 0.10 mmol) in DMA (4 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 16 hours, and the solvent was evaporated under reduced pressure to obtain a crude product. Purification on silica gel (2.5% MeOH in DCM) gave N-[2-[7-[(1R)-2-[3-(dimethylamino)propylcarbamoyl-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]-5-fluoro-phenyl]tetradecanoamide (36.8 mg, 52%). LC-MS 709.6 [M+1]+, RT 5.14 min.

[0117] Figure 4A and Figure 4B Shown are the results of mammary cell sphere formation of compound [IV] and the results of SRB assay on MCF-7 cells. Figure 4A As shown, compound [IV] had a dose-dependent inhibitory effect on MCF-7 cells at all tested concentrations, ranging from 1 μM to 10 μM. Compound [IV] showed more than 50% inhibition at 2.5 μM and almost complete inhibition at 10 μM. Figure 4B It was shown that compound [IV] exhibited cytotoxicity to MCF-7T cells starting from 5 μM.

[0118] In some embodiments, the therapeutic agent can take the form of the following compound [V], N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide, which has the following chemical structure:

[0119]

[0120] Compound [V] was synthesized as follows. In step 1, tert-butyl N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-carbamate was used as an intermediate for preparation. Isobutyl chloroformate (0.82 ml, 6.0 mmol) was added to a stirred solution of Boc-N-ethylglycine (1.02 g, 5.0 mmol) and NMM (0.79 ml, 7.5 mmol) in DCM (30 ml) at 0°C under a nitrogen atmosphere. The mixture was stirred for 1 hour, N,N-dimethylethylenediamine (0.83 ml, 7.5 mmol) was added, and the mixture was warmed to room temperature and stirred for 60 hours. The reaction mixture was diluted with DCM (30 ml), washed with saturated NaHCO (30 ml) and brine (30 ml), dried over MgSO, filtered and the filtrate evaporated under reduced pressure to give tert-butyl N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-carbamate (1.44 g) as a light brown oil. LC-MS 274.3 [M+1]+, RT 0.86 min.

[0121] In step 2, N-[2-(dimethylamino)ethyl]-2-(ethylamino)acetamide hydrochloride is prepared. A 4M HCl solution of dioxane (23 ml, 95 mmol) is added to a stirred solution of tert-butyl N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-carbamate (1.30 g, 4.8 mmol) in chloroform (30 ml) at room temperature under nitrogen atmosphere, and the mixture is stirred for 20 hours. The solvent is evaporated under reduced pressure to give N-[2-(dimethylamino)ethyl]-2-(ethylamino)acetamide hydrochloride (1.15 g) as a light brown solid. LC-MS 174.3 [M+1] +, RT 0.27 min.

[0122] In step 3, N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide was prepared from the previous product. Isobutyl chloroformate (11 μl, 0.084 mmol) was added to a stirred solution of (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoic acid (40 mg, 0.070 mmol) and NMM (23 μl, 0.21 mmol) in dry DCM (2 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 1 hour, N-[2-(dimethylamino)ethyl]-2-(ethylamino)acetamide hydrochloride (27 mg, 0.11 mmol) was added and the mixture was stirred for 17 hours. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in EtOAc (20 ml), washed with water (10 ml), brine (10 ml), dried over MgSO4, filtered and the filtrate evaporated under reduced pressure. Purification on silica gel (5-10% MeOH in DCM and 1% 7M NH3 in MeOH) gave compound [V], N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide (14.9 mg). LC-MS 725.6[M+1]+, RT 5.35min.

[0123] Figures 5A-5C The results of mammary cell sphere formation of compound [V], the results of SRB assay on MCF-7 cells, and the results of SRB assay on BJ1-hTERT cells are shown. Figure 5A Compound [V] showed effective inhibition of MCF-7 cells at all tested concentrations, ranging from 0.5 μM to 10 μM. At a concentration of 0.5 μM, more than 50% inhibition was observed, and at a concentration of 5 μM, compound [V] achieved 100% inhibition of MCF-7 cells. Figure 5B and Figure 5C It was shown that compound [V] exhibited cytotoxicity against MCF-7 and BJ1-hTERT cells starting from 5 μM.

[0124] In some embodiments, the therapeutic agent may take the form of the following compound [VI], (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid, which has the following chemical structure:

[0125]

[0126] Compound [VI] was synthesized according to the following method, and it will be appreciated that alternative methods may be used.

[0127] In step 1, methyl 2-chloro-4-(tetradecanoylamino)benzoate is used as the starting intermediate. Under nitrogen atmosphere at room temperature, tetradecanoyl chloride (2.42 g, 9.80 mmol) dry DCM (10 ml) solution is added to a suspension of stirred methyl 4-amino-2-chlorobenzoate (1.87 g, 10.1 mmol) and NMM (1.50 ml, 13.6 mmol) dry THF (30 ml) solution, and the mixture is stirred at room temperature for 20 hours. The solvent is evaporated under reduced pressure, and the residue is dissolved in EtOAc (50 ml), washed with 2M HCl (50 ml), saturated NaHCO (50 ml), brine (50 ml), dried over MgSO, filtered and the filtrate is concentrated under reduced pressure to obtain the crude product methyl 2-chloro-4-(tetradecanoylamino)benzoate as a light brown solid, (4.10 g). LC-MS396.1[M+1]+, RT 6.50min.

[0128] In step 2, compound 2-chloro-4-(tetradecanoylamino)benzoic acid is prepared. At room temperature, NaOH (8g, 200mmol) water (50ml) solution is added to the solution of stirred methyl 2-chloro-4-(tetradecanoylamino)benzoate (3.60g, 9.08mmol) THF (50ml) solution and MeOH (50ml), and the mixture is stirred for 16 hours. The solvent is evaporated under reduced pressure, the residue is acidified with 6MHCl (50ml), diluted with water (50ml), and the product is extracted with EtOAc (100ml). The extract is washed with salt water (ClH2NaO, 50ml), dried, filtered and evaporated under reduced pressure on MgSO4 to obtain the crude product 2-chloro-4-(tetradecanoylamino)benzoic acid (3.40g) of a pale yellow solid. LC-MS 382.2[M+1]+, RT 6.73min.

[0129] In step 3, 2-chloro-4-(tetradecylamino)benzoyl chloride is prepared. Under nitrogen atmosphere at room temperature, oxalyl chloride (0.91ml, 10.47mmol) is added to a suspension of 2-chloro-4-(tetradecylamino)benzoic acid (2.00g, 5.24mmol) and DMF (4 drops) dried DCM (100ml) solution of stirring. The mixture is stirred at room temperature for 20 hours, and concentrated under reduced pressure to obtain a crude product 2-chloro-4-(tetradecylamino)benzoyl chloride (2.30g) of a yellow solid. LC-MS396.3[M-OMe+1]+, RT 7.21min.

[0130] In step 4, the compound ethyl 3-[2-chloro-4-(tetradecanoylamino)phenyl]-3-oxo-propionate was prepared from 2-chloro-4-(tetradecanoylamino)benzoyl chloride as follows. TEA (1.65 ml, 11.74 mmol) and anhydrous magnesium chloride (1.28 g, 13.42 mmol) were added to a stirred suspension of potassium ethylmalonate (1.9 g, 11.19 mmol) in dry MeCN (30 ml) at +10°C under nitrogen atmosphere and stirred at room temperature for 3.5 hours. A solution of 4-fluoro-2-nitrobenzoyl chloride (1.14 g, 5.59 mmol) in dry MeCN (2 ml) prepared according to Archiv der Pharmazie, 1985, Vol. 318, No. 1, pp. 78-84 was added and the mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into a stirred mixture of saturated NH4Cl (2 ml) and EtOAc (50 ml), and the solvent was evaporated under reduced pressure. The solid residue was stirred at room temperature for 30 minutes with 4M HCl (30 ml), and the product was extracted with EtOAc (50 ml). The extract was washed with 4M HCl (30 ml), water (30 ml), brine (30 ml), dried over MgSO4, filtered and the filtrate was concentrated under reduced pressure to give a crude product. Purification on silica gel (15% EtOAc in isohexane) gave ethyl 3-[2-chloro-4-(tetradecanoylamino)phenyl]-3-oxo-propanoate (2.10 g) as a yellow solid. LC-MS 452.2 [M+1] +, RT 7.05 min.

[0131] In step 5, N-[3-chloro-4-(7-hydroxy-2-oxo-chromen-4-yl)phenyl]tetradecanoic acid amide is prepared from ethyl 3-[2-chloro-4-(tetradecanoylamino)phenyl]-3-oxo-propionate according to step 2 for preparing compound [VII] described below. This gives N-[3-chloro-4-(7-hydroxy-2-oxo-chromen-4-yl)phenyl]tetradecanoic acid amide (0.30 g) as a yellow solid. LC-MS 498.2 [M+1]+, RT 6.99 min.

[0132] In step 6, the compound ethyl (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-methyl-7-yl]oxypropanoate was prepared from N-[3-chloro-4-(7-hydroxy-2-oxo-chromen-4-yl)phenyl]tetradecanoamide according to step 4 for preparing compound [VII] described below. This gave ethyl (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoate (0.25 g) as a yellow solid. LC-MS 598.3 [M+1]+, RT 7.83 min.

[0133] In step 7, (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid, compound [VI], is prepared from ethyl (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoate according to the method of step 6 for preparing compound [VII] described below. This gave (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (0.15 g) as a light brown solid. LC-MS 570.4 [M+1]+, RT 2.65 min.

[0134] Fig. 6A and Figure 6B Results of mammary cell sphere formation and SRB assay on MCF-7 cells for compound [VI] are shown. Inhibitory activity was observed at all tested concentrations (1 μM to 100 μM), and inhibition reached more than 50% at 10 μM. Significant improvement was observed when increasing from 50 μM to 100 μM, and further evaluation between these concentrations is envisioned. Regarding the SRB assay, compound [VI] showed little toxicity at the tested concentrations, as shown in Table 1. Figure 6B shown.

[0135] In some embodiments, the therapeutic agent may take the form of the following compound [VII], which has the following chemical structure:

[0136]

[0137] Compound [VII], (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid, was synthesized according to the following method. In step 1, ethyl 3-(4-fluoro-2-nitro-phenyl)-3-oxo-propionate was prepared. TEA (1.65 ml, 11.74 mmol) and anhydrous magnesium chloride (1.28 g, 13.42 mmol) were added to a stirred suspension of potassium ethylmalonate (1.9 g, 11.19 mmol) in dry MeCN (30 ml) at +10°C under nitrogen atmosphere and stirred at room temperature for 3.5 hours. Add according to Archiv der Pharmazie, 1985, volume 318, the 1st phase, 4-fluoro-2-nitrobenzoyl chloride (1.14g, 5.59mmol) dry MeCN (2ml) solution of 78-84 page preparation, and at room temperature stir mixture 16 hours.Reaction mixture is poured into the saturated NH of stirring in Cl (2ml) and the mixture of EtOAc (50ml), and evaporated under reduced pressure solvent.Solid residue was stirred at room temperature 30 minutes with 4M HCl (30ml), and product was extracted with EtOAc (50ml).Extract 4M HCl (30ml), water (30ml), salt solution (30ml) washing, at MgSO Upper drying, filtration and concentrated filtrate under reduced pressure, to obtain thick product. Purification on silica gel (15% EtOAc in isohexane) gave ethyl 3-(4-chloro-2-nitro-phenyl)-3-oxo-propanoate (1.16 g, 81%). LC-MS 256.1 [M+1]+, RT 4.08 min.

[0138] In step 2, 4-(4-fluoro-2-nitro-phenyl)-7-hydroxy-chromen-2-one is prepared as an intermediate. Resorcinol (0.31 g, 2.20 mmol) is added to a stirred solution of ethyl 3-(4-fluoro-2-nitro-phenyl)-3-oxopropanoate (0.60 g, 2.30 mmol) methanesulfonic acid (4 ml) solution at room temperature under nitrogen atmosphere, and the mixture is stirred at +45°C for 1 hour. The reaction mixture is cooled to room temperature, poured into a mixture of water: EtOAc (40 ml: 10 ml), and the product is extracted with EtOAc (50 ml). The extract is washed with water (40 ml), brine (40 ml), dried over MgSO4, the solid residue is removed by filtration, and the solvent is evaporated under reduced pressure to obtain a crude product. Purification on silica gel (40-50% EtOAc in isohexane) gave 4-(4-fluoro-2-nitro-phenyl)-7-hydroxy-chromen-2-one (0.43 g, 65%). LC-MS 302.1 [M+1]+, RT 4.22 min.

[0139] In step 3, 4-(2-amino-4-fluoro-phenyl)-7-hydroxy-chromen-2-one is prepared. Under nitrogen atmosphere, trichlorosilane (0.35 ml, 3.5 mmol) in dry DCM (2 ml) is added to a stirred solution of 4-(4-fluoro-2-nitro-phenyl)-7-hydroxy-chromen-2-one (0.21 g, 0.70 mmol) in dry DCM (5 ml) and an ice-cold solution of DiPEA (0.60 ml, 3.50 mmol) over 10 minutes. The mixture is stirred at +0°C for 1 hour, quenched with saturated NaHCO (3 ml), diluted with water (20 ml) and EtOAc (30 ml) to give a suspension, which is filtered through a Celite pad. Solid NaHCO3 was added to adjust the pH to 8-9, the organic phase was separated, washed with brine (20 ml), dried over MgSO4, filtered and the solvent evaporated under reduced pressure to give the crude product. Purification on silica gel (40-50% EtOAc in isohexane) gave 4-(2-amino-4-fluoro-phenyl)-7-hydroxy-chromen-2-one (0.20 g, 99%). LC-MS 302.1 [M+1]+, RT 4.22 min.

[0140] In step 4, ethyl (2R)-2-[4-(2-amino-4-fluoro-phenyl)-2-oxo-chromen-7-yl]oxypropanoate is prepared as an intermediate. DEAD (293 μl, 1.86 mmol) is added to a stirred ice-cold solution of 4-(2-amino-4-fluoro-phenyl)-7-hydroxy-chromen-2-one (0.33 g, 1.24 mmol), S-ethyl lactate (212 μl, 1.86 mmol) and triphenylphosphine (0.32 ml, 1.24 mmol) in anhydrous THF (10 ml) under a nitrogen atmosphere. The mixture is stirred at +0°C for 0.5 hours, allowed to warm to room temperature and stirred for 16 hours. The solvent is evaporated under reduced pressure to give a crude product. Purification on silica gel (50% diethyl ether in isohexane) gave ethyl (2R)-2-[4-(2-amino-4-fluoro-phenyl)-2-oxo-chromen-7-yl]oxypropanoate (0.43 g, 93%). LC-MS 372.3 [M+1]+, RT 5.12 min.

[0141] In step 5, ethyl (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoate is prepared. Tetradecanoyl chloride (380 μl, 1.40 mmol) is added in two portions to a stirred solution of ethyl (2R)-2-[4-(2-amino-4-fluoro-phenyl)-2-oxo-chromen-7-yl]oxypropanoate (0.26 g, 0.70 mmol) in dry pyridine (3 ml) at room temperature under nitrogen atmosphere. The mixture is stirred for 16 hours and the solvent is evaporated under reduced pressure to give a crude product. The residue is dissolved in isopropanol (10 ml), diluted with EtOAc (20 ml), washed with saturated NaHCO (20 ml), brine (20 ml), dried over MgSO, filtered and the solvent is evaporated under reduced pressure to give a crude product. Purification on silica gel (10-15% EtOAc in isohexane) gave ethyl (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoate (0.21 g, 51%). LC-MS 580.4 [M+1]+, RT 7.20 min.

[0142] In step 6, (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid, compound [VII], is prepared. 1M NaOH (2 ml, 2.00 mmol) is added to a stirred solution of ethyl (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoate (0.20 g, 0.34 mmol) in THF (4 ml) at room temperature under nitrogen atmosphere. The mixture is stirred for 5 hours, diluted with EtOAc (30 ml), washed with 2H HCl (10 ml), water (10 ml), brine (20 ml), dried over MgSO4, filtered, and the solvent evaporated under reduced pressure to give the product. Purification on silica gel (4% MeOH in DCM) gave (2R)-2-[4-[4-fluoro-2-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoic acid (0.15 g, 79%). LC-MS 554.5 [M+1]+, RT 7.00 min.

[0143] Fig. 7A and Figure 7B Results of mammary cell sphere formation and SRB assay on MCF-7 cells for compound [VII] are shown. Inhibitory activity was observed at all tested concentrations (1 μM to 10 μM), and inhibition reached more than 50% at 10 μM. At a concentration of 100 μM, compound [VII] showed 100% inhibition of MCF-7 cells. Regarding the SRB assay, Figure 7B It was shown that compound [VII] had little toxicity at the tested concentration below 100 μM.

[0144] The following exemplifies the synthesis of isobutyl N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]carbamate (shown below).

[0145]

[0146] In step 1, (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy-N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-propionamide. TFA (3 ml) was added to a stirred solution of tert-butyl N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]carbamate (0.125 g, 0.20 mmol) in dry DCM (3 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 1 hour, and the solvent was evaporated under reduced pressure to give a crude product. The residue was dissolved in EtOAc (30 ml), saturated NaHCO (10 ml), brine (10 ml), dried over MgSO, filtered and the solvent evaporated under reduced pressure to give (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy-N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-propionamide (0.11 g). LC-MS 515.0 [M+1]+, RT 3.31 min.

[0147] In step 2, isobutyl N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-]-N-ethylpropionamide was prepared from (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy-N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethylpropionamide in the absence of acid according to the procedure of step 3 of Example 6. To give tert-butyl N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethyloxy]-2-oxo-chromen-4-yl]phenyl]carbamate (10.1 mg) as a light brown solid. LC-MS 615.2 [M+1]+, RT 4.38 min.

[0148] The synthesis of N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]dodecanoic acid amide is shown below (shown below).

[0149]

[0150] Lauryl chloride (16 μl, 0.073 mmol) was added to a stirred solution of (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy-N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-propionamide (30 mg, 0.058 mmol) in methyltetrahydrofuran (2 ml) and pyridine (0.5 ml) at room temperature under nitrogen atmosphere. The mixture was stirred for 16 hours and the solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (30 ml), water (10 ml), brine (10 ml), dried over MgSO4, filtered and the solvent was evaporated under reduced pressure to give a residue dissolved in EtOAc, washed with water (10 ml), brine (10 ml), dried over MgSO4, filtered and the filtrate was evaporated under reduced pressure to give a crude product. Purification on silica gel (5-10% MeOH in DCM and 1-2% 7M NH3 in MeOH) gave N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]dodecaneamide (27.3 mg). LC-MS 697.2 [M+1]+, RT 5.47 min.

[0151] The next example describes the synthesis of N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]hexanamide (shown below).

[0152]

[0153] The title compound was prepared from (2R)-2-[4-(4-amino-2-chloro-phenyl)-2-oxo-chromen-7-yl]oxy-N-[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-N-ethyl-propionamide according to the method of Example 9 to give N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]hexanamide (20.0 mg) as a light brown solid. LC-MS 613.1 [M+1]+, RT 4.93 min.

[0154] It should be understood that in some embodiments, the lactic acid portion of the propionamide base of Formula 1 can be modified with certain side chains - or the methyl group can be replaced with hydrogen. For example, some embodiments of the compounds or pharmaceutically acceptable salts thereof according to the present method have a family chemical structure of Formula 2, as shown below:

[0155] wherein R1, R2, R3 and R4 are as described above for Formula 1, and R5 and R6 may be the same or different and may be hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or substituted pyridine, substituted or unsubstituted C2-C10 carboxyl, substituted or unsubstituted C2-C10 alkene, substituted or unsubstituted C2-C10 alkyne, substituted or unsubstituted C2-C10 ketone, substituted or unsubstituted C2-C10 aldehyde, substituted or unsubstituted C2-C10 ether, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C2-C10 amine, substituted or unsubstituted C2-C10 amide, substituted or unsubstituted C2-C10 alkylamide, substituted or unsubstituted phenol, or benzoic acid.

[0156] Preferably, R5 and R6 are the same or different and are H or a substituent in a substituted alpha-hydroxy acid (AHH). Below is an example of a structure according to the present method, showing variations of R5 and R6 and including motifs of various enantiomers thereof. It should be understood that only portions of the structure are shown and the entire structure of a given example can be understood based on Formula 2 above.

[0157]

[0158] The synthesis of compounds according to Formula 2 can generally be carried out following the general synthesis examples shown above. Below is an example of a general scheme for the synthesis of compounds according to Formula 2.

[0159]

[0160] Wherein, R1-R6 are as described above. In an exemplary embodiment, the compound may have the structure of the following compound [VIII], wherein R1 is a 14-carbonamide group, R2 is chlorine, R3 and R4 are methyl, and R5 and R6 are hydrogen:

[0161]

[0162] The IUPAC name for compound [VIII] is N-[3-chloro-4-[7-[2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide. An exemplary synthetic scheme for compound [VII] (and similar embodiments for different alkyl chain lengths) is shown below.

[0163]

[0164] In the above schemes, it should be understood that a person having the skill in the art may identify more than one method to perform one or more numbered steps. As an example, compound [VIII] can be synthesized from the intermediate N-[3-chloro-4-(7-hydroxy-2-oxo-chromen-4-yl)phenyl]tetradecanoamide using the following scheme:

[0165]

[0166] In step 1, following step 4 of the above preparation of compound [VII], the compound ethyl 2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxyacetate is prepared from N-[3-chloro-4-(7-hydroxy-2-oxo-chromen-4-yl)phenyl]tetradecanoamide. This gives ethyl 2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxyacetate (0.25 g) as a light brown solid. LC-MS 584.3 [M+1]+, RT 6.95 min.

[0167] In step 2, 2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxyacetic acid is prepared from ethyl 2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxyacetate according to the method of step 6 for preparing compound [VII] described above. This gives 2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxyacetic acid (0.05 g) as a colorless solid. LC-MS 556.1 [M+1]+, RT 6.64 min.

[0168] In step 3, N-[3-chloro-4-[7-[2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoic acid amide [VII] was synthesized by the following method: NMM (100 μl, 0.72 mmol) and EDC hydrochloride (32 mg, 0.17 mmol), HOBt aqueous solution were added under nitrogen atmosphere at room temperature. The mixture was stirred for 16 hours, and the solvent was evaporated under reduced pressure to obtain a crude product. Purification on silica gel (5-13% MeOH in DCM and 1-2% 7M NH3 in MeOH) gave N-[3-chloro-4-[7-[2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide (50 mg, 78%). LC-MS 711.5 [M+1]+, RT 5.89 min.

[0169] Another illustrative example of the embodiment is compound [IX], as shown below. The IUPAC name of compound [IX] is N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide.

[0170]

[0171] Compound [IX] was synthesized as follows. In step 1, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.23 g, 1.22 mol), 1-hydroxybenzotriazole hydrate (0.17 g, 1.22 mmol) and NMM (0.33 ml, 3.0 mmol) were added to a stirred solution of (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (see compound [VI] above) in a mixture of DCM (10 ml) and DMF (5 ml) (0.35 g, 0.61 mmol) and N-ethylglycine ethyl ester trifluoroacetate (0.22 g, 1.22 mmol) at room temperature under nitrogen atmosphere. The mixture was stirred for 16 hours, and the solvent was evaporated under reduced pressure to obtain a crude product. Purification on silica gel (50-100% EtOAc in isohexane) gave ethyl 2-[[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]-ethyl-amino]acetate (0.28 g). LC-MS 683.3 [M+1]+, RT 6.89 min.

[0172] In step 2, 2-[[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]-ethyl-amino]acetic acid was prepared from ethyl 2-[[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]-ethyl-amino]acetic acid ester according to the method in step 6 of compound [IV] to give 2-[[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]-ethyl-amino]acetic acid (0.16 g) as a light brown solid. LC-MS 655.3 [M+1]+, RT 6.63 min.

[0173] In step 3, N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-[[(2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropanoyl]-ethyl-amino]acetic acid and 1-(2-aminoethyl)pyrrolidine are prepared according to the method of step 1. -methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecaneamide (Compound [XI]) was added to give N-[3-chloro-4-[7-[(1R)-2-[[2-[2-(dimethylamino)ethylamino]-2-oxo-ethyl]-ethyl-amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecaneamide (15.9 mg) as a white solid. LC-MS 751.3 [M+1]+, RT 6.06 min.

[0174] Another illustrative example of an embodiment is compound [X], as shown below. The IUPAC name of compound [X] is N-[3-chloro-4-[7-[(1R)-2-[ethyl-[2-[(1-methylpyrrolidin-3-yl)amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide.

[0175]

[0176] Compound [X] was prepared from (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (compound [VI]) and 1-methylpyrrolidin-3-amine according to the method in step 1 of compound [IX] to give N-[3-chloro-4-[7-[(1R)-2-[ethyl-[2-[(1-methylpyrrolidin-3-yl)amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide (16.4 mg) as a white solid. LC-MS 737.4 [M+1]+, RT 5.97 min.

[0177] Another illustrative example of the embodiment is compound [XI], as shown below. The IUPAC name of compound [XI] is N-[3-chloro-4-[7-[(1R)-2-[ethyl-[2-(isopentylamino)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide.

[0178]

[0179] Compound [XI] was prepared from (2R)-2-[4-[2-chloro-4-(tetradecanoylamino)phenyl]-2-oxo-chromen-7-yl]oxypropionic acid (compound [VI]) and 3-methylbutylamine according to the method in step 1 of compound [IX] to give N-[3-chloro-4-[7-[(1R)-2-[ethyl-[2-(isopentylamino)-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethoxy]-2-oxo-chromen-4-yl]phenyl]tetradecanoamide (24.9 mg) as a white solid. LC-MS 724.4 [M+1]+, RT 6.78 min.

[0180] The following abbreviations are used in the description of the synthetic methods and reaction schemes: acetonitrile (MeCN), ethyl acetate (EtOAc), methanol (MeOH), hydrochloric acid (HCl), magnesium sulfate (MgSO4), diisopropylethylamine (DiPEA), dichloromethane (DCM), sodium bicarbonate NaHCO3, isopropyl alcohol (IPA), tetrahydrofuran (THF), ammonium chloride (NH4Cl), sodium hydroxide (NaOH), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCHCl), triethylamine (TEA), N-methylmorpholine (NMM), diethyl azodicarboxylate (DEAD), dimethylacetamide (DMA), dimethylformamide (DMF), ammonia (NH3) and 4-dimethylaminopyridine (DMAP), trifluoroacetic acid (TFA), 1-hydroxybenzotriazole (HOBt), ammonia (NH3).

[0181] LC-MS data were prepared using a Waters Sunfire C18 30x4.6 mm column. Gradient eluent: 20-100% acetonitrile / water with 0.05% formic acid. Time: 0-10 minutes.

[0182] Further efficacy and toxicity evaluation was performed on human breast tumors initiated by the MDA-MB-231 cell line from chicken embryos using the chick chorioallantoic membrane assay ("CAM assay") provided by Inovotion (Cambridge, MA). The compounds of the present method showed significant effects on the metastasis of MDA-MB-231 cancer cells and were not toxic to embryos in vivo. 6 The MDA-MB-231 cell inoculum was added to the CAM of each egg (E9 day), and then the eggs were randomly grouped. On E10 day, tumors were able to be detected, and then treated with vehicle (1% DMSO in PBS solution) or the compound of the present method alone every day for 8 days. After 8 days of drug administration, all tumors were weighed on E18 day, and the lower CAM was collected to evaluate the number of metastatic cells, which were analyzed by qPCR with specific primers for human Alu sequences.

[0183] Figure 8 The quantitative evaluation of tumor growth using the CAM assay is shown for different concentrations of the embodiment compound [III] of the present method. The results show that the tumor growth of the cells is reduced in a dose-dependent manner, indicating the pharmaceutical activity of the exemplary compound. Similar activities exist in other compounds disclosed herein. Fig. 9 Quantitative assessment of metastatic invasiveness using the CAM assay is shown for various concentrations of compound [III], an embodiment of the present method. For this exemplary compound, a dose-dependent reduction in metastasis is evident. Other compounds described herein have similar activity. Figure 8 and Fig. 9 , Data were analyzed by t-test, P>0.05. Single * indicates P<0.05, ** indicates P<0.001, and **** indicates P>0.0001. Fig.10 The toxicity evaluation of compound [III] at different concentrations using the CAM assay is shown. It can be seen that the example compound is not toxic to normal cells. According to this method, selectivity for metabolically active cancer stem cells is a common property of the compounds. Table 1 below summarizes the toxicity analysis from the CAM assay.

[0184]

[0185] Table 1. Chicken embryo toxicity of compound [III].

[0186] This indicates that the compounds of the present method are effective in preventing metastasis or reducing the likelihood of metastasis. It should be understood that in embodiments of the present method, the same CAM assay can be used to replicate these properties. In addition, little or no embryotoxicity was observed for the exemplified compounds using the CAM assay. The disclosed compounds have the efficacy of acting as antimetastatic agents, selectively inhibiting tumor metastasis, without significant toxicity or antimicrobial activity.

[0187] To examine the effects of compounds described herein on mitochondrial respiration and aerobic glycolysis, adherent MCF7 cells were treated with exemplary compounds, and then OCR and ECAR were measured. Fig.11A -D shows the results of mitochondrial respiration, basal respiration, maximum respiration and ATP production for metabolic flux analysis of MCF7 cells treated with compound [III] at 2.5 μM. After treatment, mitochondrial oxygen consumption rate (OCR) was measured using a hippocampus XFe96 analyzer. Data are expressed as a percentage of OCR to the control group.

[0188] Fig. 12A-D shows the results of glycolytic function analysis for treatment with compound [III] at 2.5 μM. They are glycolytic function, basal glycolysis, inducible glycolysis and compensatory glycolysis respectively. The data show that compared with the control group cells using vehicle alone, compound [III] significantly inhibited the basal and maximum OCR and ATP production levels. On the contrary, the ECAR levels between the control group and the exemplary compound are roughly equivalent. These results are consistent with the preliminary evaluation of other compounds described herein, although the evaluation of different compounds and compound concentrations is still in progress. All data are normalized by cell number. Statistical analysis uses one-way analysis of variance.

[0189] These data directly validate how compound [III] specifically acts as a mitochondrial inhibitor of respiration and ATP production, with little effect on glycolysis. Further, the results are consistent with the understanding that the compounds of the present method (such as compound [II]) are inhibitors of mitochondrial transcription (IMT) by targeting the POLRMT enzyme.

[0190] The following paragraphs describe the materials and tests used to generate the data described herein. It should be understood that a person skilled in the art with an ordinary level of skill in the art can perform the same tests as described herein, and / or can utilize other tests known in the art to evaluate the physical, chemical and pharmaceutical properties of the compounds described herein.

[0191] Reagents and model cell lines: Obviously, other cell lines can be used without departing from the present method. The human breast cancer cell line MCF-7 is from the American Type Culture Collection (ATCC). hTERT-BJ1 cells are from MCF-7 of Clontech, and hTERT-BJ-1 cells are cultured in DMEM supplemented with 10% fetal bovine serum, GlutaMAX and 1% penicillin-streptomycin and incubated at 37°C in a humidified 5% CO2 incubator. The culture medium is changed 2-3 times a week.

[0192] 3D anchorage-independent growth assay: This assay is also called a spheroid formation assay. Single-cell suspensions were prepared using enzymes and manual dissociation (25-g needle). Cells were then plated at 500 cells / cm under non-adherent conditions. 2The cells were seeded at a density of 100 μg / ml in mammary cell sphere culture medium (DMEM-F12 + 1X B-27Plus supplement + 20 ng / ml EGF + penicillin / streptomycin) in a culture dish called "mammary cell sphere plate" pre-coated with (2-hydroxyethyl methacrylate) (poly-HEMA, Sigma Aldrich Inc). The cells were grown for 5 days and maintained in a humidified 37°C incubator. After 5 days of culture, 3D-mammary cell spheres of >50 μm were counted using an eyepiece ("grid"), and the percentage of cells that formed cell spheres was calculated and called the mammary cell sphere formation percentage, and normalized to 1 (1 = 100% MFE). The 3D mammary cell sphere formation efficiency (MFE) was analyzed in low ATP and high ATP subpopulation cells. All 3D mammary cell sphere experiments were performed three times, at least 3 times independently.

[0193] Statistical analysis: All analyses were performed using GraphPad Prism 6. Data are presented as mean ± standard deviation (or ± SEM, where indicated). All experiments were performed at least 3 times independently, with >3 technical replicates per experimental condition (unless otherwise indicated, e.g., when representative data are shown). Statistically significant differences were determined using Student's t-test or analysis of variance (ANOVA) tests. For comparisons between multiple groups, one-way ANOVA was used to determine statistical significance. p < 0.05 was considered significant.

[0194] The present method includes a method for confirming cell viability. One or more methods can be selected by those skilled in the art to confirm cell viability suitable for a particular embodiment. The inventors initially used a sulphorhodamine (SRB) assay based on measurement of cell protein content. After treatment in a 96-well plate for 72 hours, cells were fixed in a cold room with 10% trichloroacetic acid (TCA) for 1 hour and dried overnight at room temperature. Then, the cells were incubated with SRB for 15 minutes, washed twice with 1% acetic acid, and air-dried for at least 1 hour. Finally, the protein-binding dye was dissolved in a solution of 10mM Tris, pH 8.8, and read at 540nm using a plate reader. Using the SRB assay, the inventors only selected compounds that consumed ATP levels without significant cytotoxicity for further analysis. Significant cytotoxicity is defined as less than 30% of cells still on the plate. Of course, embodiments using other cell activity confirmation methods can select compounds for further analysis based on other considerations known in the art.

[0195] The therapeutic agent can be used in the form of a pharmaceutical composition, which can be prepared using one or more known methods. For example, the pharmaceutical composition can be prepared by using a diluent or excipient, such as, for example, one or more fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, etc., which are well known in the art. Various types of administration unit forms can be selected according to the therapeutic purpose. Examples of the form of the pharmaceutical composition include, but are not limited to, tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injection preparations (solutions and suspensions), topical creams, and other forms known in the art. In order to form a pharmaceutical composition in the form of a tablet, any known excipient can be used, for example: carriers, such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, cyclodextrin, crystalline cellulose, silicic acid, etc.; binders, such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrrolidone, etc. In addition, disintegrants such as dry starch, sodium alginate, agar powder, kelp powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitol fatty acid esters, sodium lauryl sulfate, monoglyceride of stearic acid, starch, lactose, etc. can also be used. Disintegration inhibitors such as white sugar, stearic acid, coconut oil, hydrogenated oil can be used; absorption promoters such as quaternary ammonium bases, sodium lauryl sulfate, etc. can be used. Wetting agents such as glycerol, starch and other wetting agents known in the art can be used. Adsorbents such as, for example, starch, lactose, kaolin, bentonite, colloidal silicic acid, etc. can be used. Lubricants such as pure talc, stearate, boric acid powder, polyethylene glycol, etc. can be used. If tablets are needed, they can be further coated with commonly used coating materials to make the tablets into sugar-coated tablets, gelatin film-coated tablets, enteric-coated tablets, film-coated tablets, double-layer tablets and multi-layer tablets. The pharmaceutical composition suitable for topical application can be formulated as an ointment, cream, suspension, lotion, powder, solution, paste, gel, foam, spray, aerosol or oil. Such pharmaceutical composition can include conventional additives, including but not limited to preservatives, solvents that assist drug penetration, cosolvents, emollients, propellants, viscosity modifiers (gelling agents), surfactants and carriers.

[0196] The present method can be used to prevent tumor recurrence, metastasis and / or reduce the possibility of tumor recurrence and metastasis. Anticancer treatments often fail because of tumor recurrence or metastasis, especially after surgery. The activity of CSC mitochondria is at least in part the reason for the failure of these treatments. Embodiments of the present method can be used in the case of conventional cancer treatment failure, and / or used in combination with anticancer treatment to prevent failure caused by tumor recurrence and / or metastasis or reduce the possibility of failure due to tumor recurrence and / or metastasis.

[0197] The present method provides a method for selectively targeting cancer cells. The targeted cancer cells can be at least one of CSC, energetic cancer stem cells (e-CSC), circulating tumor cells (CTC, seed cells that lead to subsequent growth of more tumors in distant organs, a mechanism that leads to a large part of cancer-related deaths) and therapy-resistant cancer cells (TRCC, cells that have become resistant to one or more chemotherapy, radiotherapy and other common cancer treatments).

[0198] As described in Applicant's co-pending U.S. Provisional Patent Application Nos. 62 / 686,881, filed on June 19, 2018, and 62 / 731,561, filed on September 14, 2018, which are incorporated herein by reference in their entirety, e-CSCs represent a CSC phenotype associated with proliferation. In addition to bulk cancer cells and CSCs, it should be understood that the present method can be used to target a highly proliferative subpopulation of cells that the inventors call e-CSCs, which show a gradual increase in stemness markers (ALDH activity and mammary cell sphere formation activity), a high increase in mitochondrial mass, and an increase in glycolysis and mitochondrial activity.

[0199] In view of the above, it should be understood that, depending on the embodiment, the present method can take a variety of forms. For example, the embodiment of the present method can take the form of a composition, and in particular the form of a pharmaceutical composition. The therapeutic compound can be an active ingredient and can be present in a pharmaceutically effective amount.

[0200] Embodiments of the present method can also take the form of a method for preventing at least one of tumor recurrence and metastasis or reducing the likelihood of at least one of tumor recurrence and metastasis. In some embodiments, an effective amount of a composition having a compound of the present method as a therapeutic agent can be administered. In some embodiments, an effective amount of a composition having an embodiment of a compound described herein as its therapeutic agent can be administered.

[0201] The terms used in the description of the present invention herein are only used to describe specific embodiments and are not intended to limit the present invention. As used in the description of the present invention and the description of the appended claims, unless the context clearly indicates otherwise, the singular forms "a / an" and "the" are also intended to include plural forms. The present invention includes many replacements, modifications and equivalents, as will become apparent from consideration of the following detailed description.

[0202] It should be understood that although the terms "first", "second", "third", "a)", "b)" and "c)" etc. can be used to describe various elements of the present invention herein, and the claims should not be limited by these terms. These terms are only used to distinguish one element of the present invention from another element. Therefore, the first element discussed below can be referred to as element aspect, and similarly, the third element can be referred to as element aspect without departing from the teachings of the present invention. Therefore, the terms "first", "second", "third", "a)", "b)" and "c)" etc. are not intended to convey a sequence or other hierarchy to the relevant elements, but are only used for identification purposes. The order of operations (or steps) is not limited to the order proposed in the claims.

[0203] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. It will also be understood that terms, such as those defined in common dictionaries, should be interpreted as having the same meaning as that in the context of the present application and the related art, and unless clearly defined herein, should not be interpreted in an idealized or overly formal sense. The terms used in the present description herein are only used to describe specific embodiments and are not intended to limit the present invention. All publications, patent applications, patents and other references mentioned herein are all incorporated herein by reference. In the event of a conflict in terms, this specification is controlling.

[0204] Furthermore, as used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of a combination when interpreted in the alternative ("or").

[0205] Any and all possible combinations of the listed items, as well as the lack of a combination when construed in the alternative ("or").

[0206] The terms "decrease," "lower," "lessen," and "reduce" generally refer to the ability of a composition according to the present method to produce and / or elicit a lesser physiological response (i.e., a measurable downstream effect) than that elicited by a vehicle or control molecule / composition, e.g., a reduction in tumor volume. A "decrease" or "reduced" response is generally a "statistically significant" response, and can include a 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more fold (e.g., 500, 1000 fold) decrease (including all integers and decimals between and above 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.) over the response produced by a normal, untreated or control treated subject.

[0207] The phrase "treatment cycle" refers to a course of treatment, such as a regular or predetermined repetitive dosing schedule. A treatment cycle can include several days of treatment and several days of rest. By way of example only, in a 4-week treatment cycle, the agent may be administered daily for two weeks, followed by two weeks of no treatment. It should be understood that the treatment cycle may depend on many factors, such as the disease state, age, sex, and weight of the individual, as well as the specific agent and / or method to elicit a desired response in the individual.

[0208] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. In addition, the present invention also contemplates that in some embodiments of the present invention, any feature or combination of features set forth herein can be excluded or omitted. For illustration, if the specification states that a composite includes components A, B, and C, it is specifically intended that any one or combination of A, B, or C can be omitted and disclaimed.

[0209] As used herein, the term "about" when referring to a measurable value, such as, for example, an amount or concentration, is intended to include variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount. Ranges provided herein for measurable values ​​may include any other ranges and / or individual values ​​therein.

[0210] Having thus described certain embodiments of the present invention, it should be understood that the invention defined by the appended claims is not limited to the specific details set forth in the foregoing description, since many obvious variations thereof are possible without departing from the spirit or scope thereof, as hereinafter required.

Claims

1. A compound having the following chemical structure or a pharmaceutically acceptable salt thereof: in: R1 and R2 may be the same or different and are selected from halogen, CF2H, -CF3, -OCF2H, -OCF3, substituted or unsubstituted C5-C18 carboxyl, substituted or unsubstituted C5-C18 alkane, substituted or unsubstituted C5-C18 olefin, substituted or unsubstituted C5-C18 cycloolefin, substituted or unsubstituted C5-C18 alkyne, substituted or unsubstituted C5-C18 ketone, substituted or unsubstituted C5-C18 aldehyde, substituted or unsubstituted C5-C18 ether, substituted or unsubstituted C5-C18 ester, substituted or unsubstituted C5-C18 amine, substituted or unsubstituted C5-C18 amide, substituted or unsubstituted C5-C18 alkylamide, monocyclic or polycyclic aromatic hydrocarbon, heteroaromatic hydrocarbon, phenol or benzoic acid; and R3 and R4 may be identical or different and are selected from hydrogen, substituted or unsubstituted C2-C18-alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C18 carboxyl, substituted or unsubstituted C2-C18 alkene, substituted or unsubstituted C2-C18 alkyne, substituted or unsubstituted C2-C18 ketone, substituted or unsubstituted C2-C18 aldehyde, substituted or unsubstituted C2-C18 ether, substituted or unsubstituted C2-C18 ester, substituted or unsubstituted C2-C18 amine, substituted or unsubstituted C2-C18 amide, substituted or unsubstituted C2-C18 alkylamide, substituted or unsubstituted phenol or benzoic acid, or one of R3 and R4 is a radical and the other of R3 and R4 is H or C2-C5 alkyl; or, R3 and R4 form a substituted or unsubstituted C5 or C6 heterocycle; or, R3 and R4 form a group Or NR3R4 is OH; · Provided that at least one of R1 and R2 is a substituted or unsubstituted C5-C18 amide, or at least one of R3 and R4 is a group And the other of R3 and R4 is H or C2-C5 alkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

8. The compound according to claim 1, wherein One of R1 and R2 is halogen.

9. The compound according to claim 1, wherein One of R3 and R4 is a group And the other is C2-C5 alkyl.

10. The compound according to claim 1, wherein One of R3 and R4 is a group And the other is C2-C5 alkyl.

11. The compound according to claim 1, wherein R3 and R4 form a group 12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

14. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

16. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure 17. A compound having the following chemical structure or a pharmaceutically acceptable salt thereof: in: R1 and R2 may be the same or different and are selected from halogen, CF2H, -CF3, -OCF2H, -OCF3, substituted or unsubstituted C5-C18 carboxyl, substituted or unsubstituted C5-C18 alkane, substituted or unsubstituted C5-C18 olefin, substituted or unsubstituted C5-C18 cycloolefin, substituted or unsubstituted C5-C18 alkyne, substituted or unsubstituted C5-C18 ketone, substituted or unsubstituted C5-C18 aldehyde, substituted or unsubstituted C5-C18 ether, substituted or unsubstituted C5-C18 ester, substituted or unsubstituted C5-C18 amine, substituted or unsubstituted C5-C18 amide, substituted or unsubstituted C5-C18 alkylamide, monocyclic or polycyclic aromatic hydrocarbon, heteroaromatic hydrocarbon, phenol or benzoic acid; R5 and R6 may be the same or different and are selected from hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or substituted pyridine, substituted or unsubstituted C2-C10 carboxyl, substituted or unsubstituted C2-C10 alkene, substituted or unsubstituted C2-C10 alkyne, substituted or unsubstituted C2-C10 ketone, substituted or unsubstituted C2-C10 aldehyde, substituted or unsubstituted C2-C10 ether, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C2-C10 amine, substituted or unsubstituted C2-C10 amide, substituted or unsubstituted C2-C10 alkylamide, substituted or unsubstituted phenol, or benzoic acid; and R3 and R4 may be identical or different and are selected from hydrogen, substituted or unsubstituted C2-C18-alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C18 carboxyl, substituted or unsubstituted C2-C18 alkene, substituted or unsubstituted C2-C18 alkyne, substituted or unsubstituted C2-C18 ketone, substituted or unsubstituted C2-C18 aldehyde, substituted or unsubstituted C2-C18 ether, substituted or unsubstituted C2-C18 ester, substituted or unsubstituted C2-C18 amine, substituted or unsubstituted C2-C18 amide, substituted or unsubstituted C2-C18 alkylamide, substituted or unsubstituted phenol or benzoic acid, or one of R3 and R4 is a radical and the other of R3 and R4 is H or C2-C5 alkyl; or, R3 and R4 form a substituted or unsubstituted C5 or C6 heterocycle; or R3 and R4 form a group or NR3R4 is OH; Provided that at least one of R1 and R2 is a substituted or unsubstituted C5-C18 amide, or at least one of R3 and R4 is a group And the other of R3 and R4 is H or C2-C5 alkyl.

18. The compound according to claim 17 or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure:

19. The compound according to claim 17, wherein R5 and R6 are selected from the group consisting of:

20. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier.

21. A method for treating or preventing tumor recurrence and / or metastasis, the method comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising a compound according to any one of claims 1 to 14 to a patient at risk of tumor recurrence and / or metastasis.

22. The method according to claim 16, wherein: The administering is performed at least one of before cancer treatment, during cancer treatment, and after cancer treatment.

23. A method for inhibiting the proliferation of cancer stem cells in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising a compound according to any one of claims 1 to 14.

24. The method according to claim 18, wherein: The administering is performed at least one of before cancer treatment, during cancer treatment, and after cancer treatment.

25. A method for treating cancer, the method comprising: A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 is administered to a cancer patient in a pharmaceutically effective amount.

26. The method of claim 18, wherein: The administering is performed at least one of before cancer treatment, during cancer treatment, and after cancer treatment.